Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaozhi Hugan Capsule is a Traditional Chinese Medicine (TCM) formulation approved in China for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hyperlipidemia. The capsule contains a mixture of herbal extracts, typically including *Crataegi Fructus* (Hawthorn), *Alismatis Rhizoma* (Water Plantain), *Cassiae Semen*, *Nelumbinis Folium* (Lotus Leaf), *Bupleuri Radix*, and *Curcumae Longae Rhizoma* (Turmeric). Its therapeutic effects are attributed to its ability to regulate lipid metabolism, reduce hepatic fat accumulation, and provide hepatoprotective activity by lowering serum transaminase levels (ALT and AST). It is widely utilized in clinical practice in China to improve liver function and ultrasound outcomes in patients with metabolic-associated fatty liver disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiaozhi hugan capsule.